// App-Quantinova.ai

TPS3112 : A phase I dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.

Researchers

Presenter

  • Kenji Hashimoto

Principal Investigators

  • Ayesh Perera

  • Naofumi Sugaya

  • Yoshitaka Ogita

  • Mikiko Nakamura

  • Sheila Rossi

  • Takahiro Ishiguro

  • Yuji Sano

  • Sumire Shimada

  • Werner Frings

  • Shun-ichiro Komatsu

  • Akihisa Kaneko

  • Masamichi Ueda

  • Junnosuke Matsushima

  • Shohei Kishishita

  • Athos Gianella-Borradori

  • ASCO ERY

Medical Centers

  • Chugai Pharma Europe, London, United Kingdom

  • Chugai Pharma Europe, London, United Kingdom

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Chugai Pharma USA, Barkeley Heights, NJ

  • Chugai Kamakura Research Laboratories, Kamakura, Japan

  • Chugai Fuji Gotemba Research Laboratories, Gotemba, Japan

Locations

  • United States

  • United Kingdom

  • Japan

Companies

  • Chugai Pharma UK Ltd

  • Chugai Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 2AP

  • Glypican-3

  • Twist-related protein 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02748837

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved